In contrast, Kunitz-type protease inhibitor 2 (SPINT2) and prostate cancer, as well as Semaphorin-3G (SEMA3G) and CRC, were shown to have distinct variants at the gene target (i.e. PPH3 > 0.8; Supplementary Data 6). This evidence concerns the gene SPINT2 and Familial prostate cancer.